Everyone likes the idea of paying less for medical care, but the real win comes when lower spending does not drag quality down with it. To keep this headline honest, I treated “costs less” as countries whose overall health spending per person sits well below the United States, which the OECD estimated at more than $14,880 per capita in 2024. From there, I looked for places that still post strong signals on life expectancy, treatable mortality, preventable deaths, or key hospital outcomes. That leaves a much better list than one built on vague reputation alone.
One caveat belongs near the top. A strong national system does not guarantee that every foreign visitor will pay local resident rates, because access and billing can still shift depending on insurance, residency, and whether someone uses public or private care. Still, national performance tells you a lot about the standard of treatment, the depth of the system, and the odds of finding reliable care when you need it. On that front, these eight countries make a very persuasive case.
1. Spain
Spain is one of the easiest countries to defend on this topic because the numbers feel balanced from every angle. The OECD says Spain spent $5,346 per person on health in 2024, which was below the OECD average and far below the American figure. At the same time, life expectancy reached 84 years, almost three years above the OECD average. Preventable mortality and treatable mortality both came in comfortably below the rich-country norm.
That strong value story carries into day-to-day access. Spain covers the whole population for a core set of services, and only 1.7% of people reported unmet healthcare needs, compared with an OECD average of 3.4%. Avoidable hospital admissions were also lower than average, which helps the system look sturdy rather than merely affordable. For a country spending far less than the U.S., that is a very respectable picture.
2. Japan
Japan has long been admired for longevity, and the latest OECD snapshot keeps that reputation intact. Health spending came in at $5,790 per person, slightly below the OECD average and nowhere near U.S. levels. Yet life expectancy reached 84.1 years, which was three years above the OECD average. Preventable mortality and treatable mortality were both well below the benchmark as well.
The hospital-quality indicators add extra weight. Japan’s 30-day mortality after heart attack was 4.9%, better than the OECD average of 6.5%, while 30-day mortality after stroke was only 2.1%, dramatically lower than the 7.7% OECD average. Those are the sort of figures that make a system look efficient in moments that matter most. For a country that spends less per person than the OECD average, Japan remains a standout.
3. South Korea
South Korea makes this list because the spending side is hard to ignore. The OECD says Korea spent $4,797 per person on health in 2024, clearly below the OECD average and far below the U.S. figure. Even with that leaner spend, life expectancy reached 83.5 years, which was 2.4 years above the OECD average. Treatable mortality was 45 per 100,000, far better than the OECD average of 77.
This is not a system that gets by on one flattering stat. Korea also posted lower-than-average preventable mortality and devoted 4.6% of total health spending to prevention, above the OECD average of 3.4%. Its 30-day stroke mortality rate was 3.3%, well below the OECD average, even though heart-attack mortality was higher than the benchmark. The bigger picture still looks efficient, but the strengths are clearer in prevention, life expectancy, and stroke outcomes than in every single acute-care measure.
4. Australia
Australia is not a bargain-basement system, but next to the United States, it still looks strikingly like good value. OECD data puts Australian health spending at $7,469 per person in 2024, roughly half the U.S. level. Even so, life expectancy was 83 years, 1.9 years above the OECD average. Preventable mortality and treatable mortality both beat the OECD average by a wide margin.
The acute-care figures are even more convincing. Australia recorded 30-day mortality after heart attack at 3.3% and after stroke at 4.1%, both much better than OECD averages. It also sits above the OECD average on seven of ten key health-system resource indicators. When a country spends that much less than the U.S. and still produces that kind of profile, it earns attention.
5. Netherlands
The Netherlands is probably the cleanest example of a country that spends serious money but still gets much more visible return than the United States. OECD figures show Dutch health spending at $8,436 per person in 2024, well under the American level. Life expectancy was 81.9 years, and both preventable mortality and treatable mortality were much lower than OECD averages. This is not low-cost care in absolute terms, but it is clearly better value than the U.S. model.
What really sharpens the case is how strong the hospital data looks. The Netherlands posted 30-day mortality after heart attack at 2.9%, one of the best figures in this group, and stroke mortality at 5.1%, also below the OECD average. It also performed above the OECD average on seven of ten resource indicators. That mix gives the Dutch system a reputation for being organized, dependable, and worth the price tag.
6. France
France has a way of staying in this conversation year after year because its system still looks strong on the basics. The OECD says France spent $7,367 per person on health in 2024, far below U.S. spending. Life expectancy reached 83 years, while preventable mortality and treatable mortality were both comfortably below OECD norms. Those are solid outcomes for a country that spends so much less than America.
The supporting cast is strong too. France has 5.4 hospital beds per 1,000 people, above the OECD average, and nearly the same doctor density as the OECD norm. That does not mean every appointment is instant or every region feels identical. It does mean the national system still has the depth and clinical backbone to justify its long-standing reputation.
7. Sweden
Sweden is a strong reminder that a country can spend less than the United States and still look excellent on outcomes. OECD data shows Swedish health spending at $7,871 per person in 2024, again far below the U.S. figure. Life expectancy reached 83.4 years, which was 2.3 years above the OECD average. Preventable mortality was only 86 per 100,000, and treatable mortality was 47, both notably better than the benchmark.
Sweden also looks sharp when the focus narrows to urgent care. Thirty-day mortality after heart attack was 3.4%, and 30-day mortality after stroke was 4.9%, both comfortably below OECD averages. The country also sits above the OECD average for doctors, nurses, and long-term care workers. That gives the whole system a steady, well-staffed feel that matches the outcomes.
8. New Zealand
New Zealand rounds out the list because the value equation stays attractive even without bargain-level spending. The OECD says New Zealand spent $6,097 per person on health in 2024, which is only slightly above the OECD average and still far below the U.S. level. Life expectancy was 82 years, and just 2.9% of people rated their health as bad or very bad, compared with an OECD average of 8.0%. That is a quietly impressive set of signals.
There is also a reassuring breadth to the system. New Zealand covers the entire population for a core set of services, posted higher-than-average breast cancer screening, and recorded 30-day mortality after heart attack at 4.6%, better than the OECD average. Satisfaction with the availability of quality care was basically in line with the broader OECD group. Put together, the picture is of a country that spends nowhere near U.S. levels yet still delivers credible national performance.
The bigger takeaway is simple. Spending less than the United States does not automatically mean thinner standards, weaker results, or second-rate treatment. Spain, Japan, South Korea, Australia, the Netherlands, France, Sweden, and New Zealand all show, in different ways, that a country can keep costs lower than America’s system and still produce outcomes that look strong on the OECD’s scoreboard. That is the kind of trade-off more people are paying attention to now.
Thank you Vasiliaja Mrakovic for an informative article. Hopefully, when I post this everyone on my list (in America) will read it and understand how very OVERPRICED it is here in America and DO SOMETHING about it.